Key result
Clopidogrel forms an integral component of antiplatelet therapy for preventing stent thrombosis in patients undergoing percutaneous coronary intervention, though some questions remain.
This article reviews the role of clopidogrel therapy in patients undergoing elective percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
Confirms clopidogrel's role in PCI antiplatelet therapy; leaves open questions on optimization for prospective study.
The introduction of percutaneous coronary intervention (PCI) substantially changed the treatment of patients with coronary artery disease. Stent thrombosis is the most worrisome early complication in patients undergoing PCI. Therefore, antiplatelet therapy forms an integral component of treatment with intracoronary stent implantation. A multitude of randomized and observational studies have helped identify and define the role of clopidogrel in today's PCI patient. Although much is known about its use, a number of questions still remain.
No takes yet. Share an insight, caveat, or question.
Moťovská et al. (2009) conducted a review in Coronary artery disease undergoing percutaneous coronary intervention. Clopidogrel was evaluated. Clopidogrel forms an integral component of antiplatelet therapy for preventing stent thrombosis in patients undergoing percutaneous coronary intervention, though some questions remain.
Synapse has enriched 10 related papers. Consider them for comparative context: